Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
Open Access
- 1 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 10 (3), 300-308
- https://doi.org/10.1215/15228517-2008-005
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsNeuro-Oncology, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical ProstatectomyClinical Cancer Research, 2006
- Angiogenesis and apoptosis in glioma: Two arenas for promising new therapiesJournal of Cellular Biochemistry, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Angiogenesis in malignant gliomasGlia, 1995